https://mjzanon.com/wp-content/uploads/2025/02/PharmaReportbyMJZanon-RPI2825.pdf🚨 BREAKING: Brazil’s Pharma Trademark Boom – AI, CBD, and High-Stakes IP Wars
Key insights from INPI RPI2825 data (Feb 2025):
🔍 Why This Matters for Pharma & IP Leaders:
✅ AI-Driven Drug Development: 28% of Class 5 (Pharma) filings now integrate AI (e.g., HIY.AI
Healthcare).
✅ CBD Dominance: Montjuic S.A. leads with Erb CBD Pharma Grade (+34% YoY growth!).
🔥 High-Risk Zones: 320+ oppositions in Class 5 – generic vs. branded drug wars escalate.
🌱 Untapped Opportunities: Psychedelics & telemedicine trademarks remain wide open.
📢 Act Now or Lose Ground:
1️⃣ Secure hybrid trademarks (Class 5 + 42 for AI-pharma tools).
2️⃣ Partner with CBD innovators before markets saturate.
3️⃣ Avoid São Paulo’s opposition battlegrounds – use predictive tools like TWS IP AI.
💼 Free Risk Assessment:
👉 Comment “PHARMA IP” or DM me for a custom trademark audit.
👉 REPORT
🔗 Tag Your Team:
👉 IP Attorneys | 👉 Pharma Execs | 👉 Investors
Data doesn’t lie – but your competitors won’t wait. 🔥
hashtag
hashtag#PharmaTrends hashtag
hashtag#TrademarkStrategy hashtag
hashtag#AIInHealthcare hashtag
hashtag#CBD hashtag
hashtag#BrazilIP
M. J. Zanon
Brazilian IP Attorney | Pharma IP Strategist
📩 [email protected] | 🌐 www.mjzanon.com
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
These cookies are needed for adding comments on this website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com